MIPS in major push to find new cancer drugs

pink ribbon

Monash Institute of Pharmaceutical Sciences (MIPS) researchers are collaborating with local and international colleagues to identify new treatments for cancer, one of the most burdensome of diseases in terms of its toll on individuals, families and society.

The collaborators are working through the Cooperative Research Centre for Cancer Therapeutics (CTx), whose purpose is to turn Australia's leading small-molecule cancer discoveries into new cancer drugs.

The CTx brings together pharmaceutical scientists and medicinal chemists at MIPS and other leading cancer research organisations in Australia. It also has links to Cancer Research Technology Ltd (UK), a major UK cancer drug discovery and development technology transfer company.

The centre is a significant opportunity to create Australia's first combined, pre-clinical cancer translation organisation.

Cancer presents an enormous personal, social and economic burden worldwide. It's the nation's biggest disease concern, with one in three Australians developing it before age 75.

With more than 88,000 new cases and 36,000 deaths a year, cancer causes an annual loss of nearly 480,000 disability-adjusted years of life in Australia, or almost a fifth of the estimated total for all causes of death and disability.